Non-standard abbreviations: ADCC, antibody-dependent cellular cytotoxicity; ALL, acute lymphoblastic leukemia; BM, bone marrow; CDC, complement-dependent cytotoxicity; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large b cell lymphoma; FL, follicular lymphoma; mAb, monoclonal antibody; PBS, phosphate buffered saline; PBMC, peripheral blood mononuclear cell; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; Tg, transgenic. 
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Introduction
B lymphocytes are an important component of the immune system and are the source of humoral immunity. However, B cells can also be pathogenic and the origin of disease.
Deregulated B cell function has been implicated in several autoimmune diseases, including systemic sclerosis, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) Gabrielli et al, 2009 ). B cells contribute to pathological immune responses through the secretion of cytokines, co-stimulation of T cells, antigen presentation, and the production of autoantibodies (Browning, 2006; Walker and Fritzler, 2007; Yanaba et al, 2008) . Furthermore, the majority of human leukemias and lymphomas are of B-cell origin (Kuppers, 2005) . Despite recent advances in the clinic, B cell malignancies, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B cell lymphoma (DLBCL), still present a significant challenge and curative treatment is not possible in most cases (Coffier et al, 2005a; Coffier et al, 2005b ).
B cell depletion by targeting B cell restricted cell surface antigens with monoclonal antibodies (mAbs) has gained significant attention in recent years. In particular, the CD20 mAb rituximab, which is already approved for the treatment of NHL and DLBCL, has shown promising results in the treatment of B cell malignancies. While the combination of rituximab with chemotherapy has led to significant improvements in patient survival in FL and other malignancies, many patients relapse after treatment (Maloney, 2005) . In addition, low CD20 expression has been associated with poor response to rituximab in DLBCL, and rituximab treatment can lead to down-regulation of CD20 or the selection of CD20-deficient tumor clones (Johnson et al, 2009; Davis et al, JPET #168062 5 1999 ; Kennedy et al, 2004) . Rituximab has also shown activity in autoimmune diseases, in particular in RA, but reductions in the levels of circulating autoantibodies, which may play an important role in SLE and other indications, are not consistent (Levesque and St Clair, 2008; Tedder, 2009 ).
CD19 is a B cell-specific surface antigen that is expressed by early pre-B cells from the time of heavy chain rearrangement until the molecule is eventually down-regulated during terminal differentiation into plasma cells (Nadler et al, 1983) . CD19 belongs to the immunoglobulin domain-containing superfamily of transmembrane receptors. As a component of the B-cell receptor complex, CD19 regulates the threshold for B-cell activation (Engel et al, 1995) . Relatively small changes in CD19 surface expression can lead to loss of tolerance and autoantibody production (Sato et al, 2004) .
In hematopoietic malignancies of B cell origin, expression of CD19 is maintained following malignant transformation of B cells and the majority of B cell-derived leukemias and lymphomas consistently express CD19 (D'Arena et al, 2000) .
Importantly, malignant B cells that have lost CD20 expression during the course of rituximab therapy maintain expression of CD19 (Johnson et al, 2009 ). Thus, CD19 is an attractive target for antibody-mediated B cell depletion therapy in multiple hematologic malignancies. Due to the expression of CD19 on plasmablasts, which are CD20 negative (Levesque and St. Clair 2008) , a depleting CD19 mAb may also have a more significant impact than CD20 targeted therapies on the levels of pathogenic autoantibodies in autoimmune diseases (Tedder, 2009 ).
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Here we report the generation of a new anti-human-CD19 mAb in development for the therapeutic depletion of B cells. The humanized and affinity optimized MEDI-551 mAb has binding characteristics which are favorable for an ADCC-dependent mechanism.
MEDI-551 was generated by removal of the fucose carbohydrate modification from the Fc portion of the humanized CD19 mAb anti-CD19-2, which resulted in a selective increase in the affinity for human FcγRIIIA and mouse FcγRIV. The anti-CD19-2 mAb was developed by humanization and affinity optimization of the HB12b mAb, which has potent B cell depleting activity in transgenic (Tg) mice expressing human CD19 (huCD19) (Kansas and Tedder, 1991; Yazawa et al, 2005) . During in vitro ADCC assays, MEDI-551 depleted primary human B cells at lower mAb concentrations than the CD20 mAb rituximab. Furthermore, at low mAb doses, MEDI-551 is more effective than rituximab in depleting blood and tissue B cells in huCD19/CD20 double Tg mice, despite the absence of complement-dependent cytotoxcicity (CDC), which contributes to in vivo depletion with rituximab. In the Tg mouse model, macrophages are important for in vivo B cell depletion with the afucosylated human IgG1, consistent with the increased binding to mouse FcγRIV. In summary, MEDI-551 is a new anti-CD19 mAb optimized for enhanced ADCC effector function and may be found to be a useful new reagent for the treatment of B cell malignancies and B cell-dependent autoimmune disease.
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Material and Methods
Cells and reagents
The Burkitt's lymphoma cell lines Raji, Daudi and Ramos, and the human monocyte line THP-1 were obtained from the American Type Culture Collection (Manassas, VA.). The KC1333 NK cell line expressing human CD16 was obtained from BioWa Inc. (Princeton, NJ). All cell lines were maintained in RPMI medium, supplemented with 10% fetal bovine serum. Blood samples (PBMC and serum) were obtained from healthy donors after obtaining informed consent. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient centrifugation using Histopaque-1077 according to the manufacturer's instructions and B cells were purified by negative selection using the Naive B Cell Isolation Kit II according to the manufacturer's instructions (Miltenyi Biotec; Auburn, CA). The mAbs used were anti-CD22 clone S-HCL-1 (BD Immunocytometry Systems, San Jose, CA) and rituximab (Biogen Idec, Inc; Cambridge, MA) (Anderson et al, 1997) . The human IgG1 mAb R347 (MedImmune, Inc) was used as isotype control. Mouse specific mAbs used were B220 (CD45R; Invitrogen, Carlsbad, CA) and 1D3 (CD19; Becton Dickinson Pharmingen, San Diego, CA).
Antibody engineering
To generate a CD19 mAb with enhanced ADCC effector function, the mouse IgG1 mAb HB12b (Kansas and Tedder, 1991) , which recognizes human CD19, was humanized and affinity optimized, resulting in mAb anti-CD19-2. To generate a homogenously afucosylated antibody, the humanized IgG1 mAb anti-CD19-2 was expressed in a JPET #168062
FcγR from the IgG surfaces. After all binding data were collected, individual data sets were averaged for binding (Response at equilibrium, or "Req") at each concentration (C), and then fit to a 1:1 binding isotherm ("Req vs. C") plot. From this, the equilibrium binding constants, K D , were derived. Such calculations were performed with BIAevaluation software, v. 4.1 (BIAcore, Inc, Uppsala, Sweden).
ADCC assays
ADCC assays were performed with a set effector-target cell ratio of 2. 
Complement-dependent cytotoxicity assay
The CDC assay was performed using the same LDH read-out assay as the ADCC assay.
Briefly, human donor serum was collected and divided into two separate aliquods. One was treated at 56° C for 30 min to inactivate complement followed by centrifugation for 10 min at 3000 x g while the other remained untreated. Media containing Phenol-free RPMI and 10% of either heat-inactivated or non-heat inactivated serum was prepared.
Target cells were washed with PBS, resuspended in either RPMI-1640 containing heatinactivated or non-heat-inactivated serum, at a cell density of 0.4x10 6 /mL. Experimental wells were set up by combining 50 μL of the appropriate antibody dilution (in either heat inactivated or non-heat inactivated media), 50 uL of target cell suspension (in either heat inactivated or non-heat inactivated media) and 50 uL media (either heat inactivated or non-heat inactivated). Reactions were set up in triplicates and plates were incubated at 37° C/ 5% CO 2 for 4 hours. temperature for 10-20 min protected from light. 50 μL of manufacturer provided stop buffer was added and absorbance at 490 or 492 nm was measured in a plate reader. % Cytotoxicity was calculated as described above for ADCC.
B cell depletion in huCD19/CD20 transgenic mice
All mouse experiments were carried out in a pathogen-free environment at the MedImmune animal facility in accordance with IACUC approved protocols. In vivo depletion of B cells by CD19 and CD20 mAbs was evaluated in huCD19/CD20 double Tg mice, which were generated by crossing huCD19 Tg with huCD20 Tg animals (Zhou et al, 1994; Ahuja et al, 2007) . Tg mice (10-15 weeks old; 5-8 animals per group) were randomized and treated with MEDI-551 or rituximab by tail vain injection. PBS-treated animals were used as controls (3-5 animals per group). Blood, spleen and bone marrow samples were collected for further analysis using flow cytometry. B cell numbers were determined in each sample by staining with APC-Cy5.5 conjugated B220 (CD45R) and PerCP-Cy5.5 conjugated muCD19 antibodies. Single cell bone marrow and spleen cell suspensions were loaded at 1.5 million cells/well for flow cytometry analysis.
Mechanism of in vivo B cell depletion
Tg mice were treated with MEDI-551 or rituximab in the absence of complement or of one of the potential effector cell populations.
To study the contribution of complement for B cell depletion, hCD19 Tg mice were detected before mAb injection and at the study endpoint by ELISA (Immunology Consultants Laboratory, Newberg, OR) (data not shown).
To deplete NK cells and neutrophils, hCD19 Tg mice were treated with i.p. injections of 0.25 mg/mouse anti-NK1.1 (clone PK136) or anti-GR1 (clone RB6-8C5) (Biolegend; San Diego, CA), respectively (Gong et al., 2005) . Anti-NK1.1 treatment occurred every other day for five days (days -1, 1, 3). Anti-GR1 was given as a single injection (day -1).
Treatment with MEDI-551 or rituximab (10 mg/kg mAb) followed 24 hours after the first injection (day 0) . The depletion of NK cells and neutrophils was verified with FACS analysis prior to treatment with MEDI-551 or rituximab and throughout the duration of B cell depletion. NK cells were detected as CD49b+CD335+ in the blood and CD49b+Ly49+ in the spleen and bone marrow. Neutrophils were detected as CD11b+SSC high (data not shown).
To assess the role of macrophages, hCD19 Tg mice were treated with injections of liposome-encapsulated clodronate (Encapsula; Nashville, TN) (5-7 animals per group).
PBS-loaded liposomes were used as control ( 
Statistical Analysis
The data were analyzed and graphed using GraphPad Prism sofware (GraphPad Software, La Jolla, CA). Mean values and standard deviation (SD) was calculated for experiments as indicated in the figure legends. Statistics were performed using a two-tailed, two sample t test in GraphPad Prism and are determined from triplicate wells of each donor tested. Significant differences are noted by p value: *, p<0.05; **, p<0.01; ***, p<0.005.
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Results
Removal of fucose enhances the ADCC effector function of the anti-CD19-2 mAb
ADCC is an important mechanism by which therapeutic mAbs mediate target cell depletion (Glennie et al, 2007) . Engagement of effector cells requires the interaction of the mAb Fc with Fcγ receptors on the surface of NK cells, monocytes/macrophages, or neutrophils. It has been demonstrated that the removal of fucose from the carbohydrate modification of the mAb Fc preferentially increases the affinity to FcγRIIIA, resulting in increased ADCC effector function (Shields et al, 2002; Nimmerjahn and Ravetch, 2008) .
To generate a CD19 mAb with enhanced effector function, the humanized and affinity optimized CD19 mAb anti-CD19-2 was expressed in a fucosyltransferease deficient CHO FcγRIIIA resulted in a substantial enhancement of its ADCC activity in vitro ( Figure 1A ).
This increase in ADCC effector function was reflected in a lower EC50 value for cytotoxicity (3.1 ng/ml for MEDI-551 versus 57.6 ng/ml for the fucosylated mAb) as well as an increase in overall cytotoxicity (50% for MEDI-551 versus 17% for mAb anti-CD19-2). In repeated assays with Daudi cells as targets, MEDI-551 was also more effective at low mAb concentrations than the rituximab CD20 mAb (EC50 = 41.0 ng/ml), which was included as a positive control ( Figure 1A ).
To further characterize the anti-CD19 mAb, we tested mAb anti-CD19-2 for additional Fc-dependent and independent effects on B cells. In addition to ADCC, CDC is an Fcdependent mechanism by which mAbs against cell surface antigens can mediate target cell killing and is well characterized for rituximab (Glennie et al, 2007) . When tested in vitro with Daudi cells and human serum as a source of complement, the anti-CD19-2 mAb was not active in a CDC assay, while the rituximab CD20 mAb showed significant cytotoxicity ( Figure 1B ).
Antibodies against cell surface antigens can also affect proliferation and/or viability of the target cell. Previous reports demonstrated that some, but not all, mAbs against CD19
can inhibit proliferation of B leukemia or lymphoma cells (Ghetie et al, 1994) . Therefore
This article has not been copyedited and formatted. The final version may differ from this version. we tested the effect of anti-CD19-2 mAb on cell proliferation of Raji, Daudi, and Ramos B lymphoma cell lines, using a luminescent viability assay. As a control, we also included the monocytic cell line THP-1. As shown in figure 1C , 
Depletion of primary human B cells ex vivo with MEDI-551
Having demonstrated potent activity in an ADCC assay with a B cell line and NK cells, The results demonstrate that MEDI-551 is active against primary human B cells in autologous ADCC assays.
MEDI-551 depletes blood and tissue B cells in vivo
Macrophages are required for efficient in vivo B cell depletion with MEDI-551
Several cell types, including NK cells, neutrophils, and macrophages, can potentially contribute to antibody-mediated target cell depletion in vivo (Glennie et al, 2007; Nimmerjahn and Ravetch, 2008) . Previous studies have emphasized the importance of Figure 5C ). Depletion of spleen B cells by MEDI-551 was much less affected by the elimination of complement with CoVF. To further confirm the contribution of macrophages for depletion of mouse B cells we tested MEDI-551 and rituximab in a phagocytosis assay with mouse peritoneal macrophages. As negative control we also included a Fc-mutated version of mAb anti-CD19-2, mAb anti-CD19-2-TM, which is devoid of effector function (Oganesyan et al, 2008) . As shown in Figure 5D , the MEDI- (Cheson and Leonard, 2008) . Targeting CD20, however, also has limitations and the antigen can be lost from malignant cells through down-regulation and/or selection (Kennedy et al, 2004; Takei et al, 2006; Davis et al, 1999) . Recent data from clinical trials of autoimmune patients treated with rituximab suggest that the depletion of memory B cells from lymphoid tissues is not always complete. Importantly, the presence of memory cells, rather than naive immature and mature B cells, at the time of repopulation was generally associated with a poor response to rituximab therapy (Leandro et al, 2006; Roll et al, 2008; Pers et al, 2008) . The broader expression along the B cell lineage and presence on most malignant B cells make CD19 an attractive alternative to CD20 for therapeutic mAb approaches.
Several different mechanisms, including ADCC, CDC, and induction of apoptosis, can lead to target cell elimination by therapeutic mAbs, such as rituximab (Glennie, 2007) .
While CDC may play a role in B cell depletion with rituximab, the contribution of direct apoptosis to in vivo B cell depletion is controversial (Glennie et al, 2007) .
In contrast to CDC and apoptosis, the relevance of ADCC and antibody-mediated phagocytosis for in vivo activity is now well established (Desjarlais et al, 2007; Glennie, 2007) . The results from this study demonstrate that MEDI-551 has potent ADCC activity, but does not mediate CDC. While potentially contributing to overall activity of CDC-competent mAbs, such as rituximab, activation of complement may also be It has been noted that in RA patients treated with rituximab clinical benefit often lasts for the duration of B cell depletion (Dorner et al, 2010) . Thus, more complete depletion of early B cells from the BM could provide additional benefit in this indication and possibly other autoimmune diseases.
Consistent with previous reports, the removal of fucose selectively increased the affinity of the IgG1 anti-CD19 mAbs to human FcγRIIIA, which is expressed on NK cells, monocytes/macrophages, and neutrophils (Shields et al, 2002; Nimmerjahn and Ravetch, 2008) . Among mouse Fcγ receptors tested, the affinity increase was limited to FcγRIV.
In contrast to human FcγRIIIA, however, mouse FcγRIV is not expressed on NK cells.
This has potential consequences for the in vivo activity when testing the afucosylated mAb in a murine model. Analysis of the effector mechanisms engaged in the mouse model by MEDI-551 clearly demonstrates an important contribution by macrophages for in vivo B cell depletion. Elimination of neutrophils or NK cells on their own had no effect on the ability of MEDI-551 to deplete B cells from blood and lymphoid tissues (data not shown). MEDI-551 also efficiently depleted splenic B cells in the absence of complement, although a minor, but statistically significant difference was observed between CoVF treated and un-treated animals ( Figure 5C ). In previous studies carried Figure 1B) . The absence of CDC activity is likely the result of the inability of the anti-CD19 mAb to mobilize the target antigen into lipid rafts, a phenomenon required for anti-CD20 mAbs to mediate CDC (data not shown) (Craigg et al, 2003) . Complement, however, was required to achieve maximal depletion of spleen B cell with rituximab ( Figure 5C ). Also using a huCD20 Tg mouse model, Gong et al (2005) investigated the mechanisms of B cell depletion with anti-huCD20 mAbs. Consistent with the findings presented here, neutralization of complement reduced the efficiency of B cell depletion in the spleen.
Interestingly, the marginal zone B cells were selectively dependent on complement for anti-CD20 mediated depletion (Gong et al, 2005) . Using wild type mice and anti-mouse-CD20 mAbs, however, Minard-Colins et al (2008) did not observe a significant contribution of complement to depletion of spleen B cells. It is possible that these different observations reflect differences in potency of the mAbs used. In the huCD19/CD20 Tg model used here, marginal zone and follicular B cells were equally susceptible to depletion with MEDI-551, despite the lack of CDC activity (data not shown). Thus, the combined in vivo data demonstrate that the afucosylated human IgG1 mAb behaves most similar to a mouse IgG2a mAb, which has the highest affinity to FcgRIV and largely relies on macrophages for target cell depletion in mouse models (Uchida et al, 2004; Gong et al, 2005; Yazawa et al, 2005 ).
As mentioned above, the affinity of mAbs for Fcγ receptors can be increased by point Downloaded from binding appears difficult, several mAbs with significantly enhanced ADCC have been reported (Bowles et al, 2006; Lazar et al, 2006) . One such mAb is XmAb5574, an anti-CD19 mAb which has been engineered for enhanced ADCC by introducing two point mutations in the Fc (Horton et al, 2008) . These mutations result in a significant increase in affinity not only to FcγRIIIA, but also to FcγRIIa and the inhibitory receptor FcγRIIb.
It is, however, difficult to compare the in vitro activity of XmAb5574 with the activity of MEDI-551, due to differences in the assay systems used. Using rituximab as a template, depletion with the two mAbs was comparable, although the onset of depletion with rituximab appeared more rapid (Cardarelli et al, 2009 ). In addition to Fc modifications, the ADCC potency of mAbs is also determined by other factors. The anti-CD19 mAb anti-CD19-2 was generated by humanization and affinity maturation, which improved the binding characteristics with decreased internalization rate, and prolonged residence time on the cell surface, features favorable for an ADCC-dependent mechanism (Herbst et al, unpublished) . Ghetie et al (1994) have shown that some, but not all, CD19 mAbs can inhibit B cell proliferation, suggesting that binding properties and/or the particular epitope recognized play an important role for this effect. Here we show that the CD19 mAb anti-CD19-2 (the fucosylated version of MEDI-551) also reduces proliferation of B cells; thus, over time, the mAb could also impact B cells in vivo, independent of ADCC effector function. To test this we also generated a Fc-mutated version of anti-CD19-2 (anti-CD19-2-TM) that is unable to bind to Fcγ receptors (Oganesyan et al, 2008 ) and compared the effect to MEDI-551 in SCID mouse human lymphoma xenograft models.
Although less potent than MEDI-551, anti-CD19-2-TM resulted in noticeable tumor growth inhibition, which is likely the result of the anti-proliferative effect of the mAb 
